Research · Sep 3, 2026
[ZBH] Zimmer Biomet Thesis 2026: Five Consecutive Years of Mid-Single-Digit Organic Growth
Zimmer Biomet FY25 (Dec 31, 2025) at $8.23B revenue (+7%). NI $705M; EPS $3.55. Persona OsteoTide knee at 35% US penetration, Z1 hip stem driving +8% US Hip Q4. Robotics +10% Q4. FY26 guide organic CC +1-3%, adj EPS $8.30-$8.45, FCF +8-10%.